Utilizzo di cellule staminali mesenchimali (MSC) da midollo osseo per la rigenerazione ossea e corneale e per l’immunoterapia della malattia da trapianto verso l’ospite (GvHD) dopo trapianto allogenico di cellule staminali emopoietiche (I)

Starting date
January 1, 2012
Duration (months)
36
Departments
Department of Engineering for Innovation Medicine, Medicine
Managers or local contacts
Krampera Mauro

Sponsors:

Regione Veneto
Funds: assigned and managed by an external body

Project participants

Activities

Research facilities

Share